Celcuity (CELC) News
NASDAQ: CELCHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CELC news summary
We found 12 recent headlines mentioning Celcuity (CELC): 0 in the past week and 8 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. CELC is making an outsized move today, down 5.26% at $53.35, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer", was published by GlobeNewswire on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Celcuity headlines
- Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast CancerFDA assigned a PDUFA goal date of June 25, 2027 FDA assigned a PDUFA goal date of June 25, 2027GlobeNewswire
- Celcuity Inc. Reports Third Quarter 2026 Financial Results and Commercial Launch of REVTORPYKCelcuity Inc. announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update on the commercial launch of REVTORPYK. The drug became commercially…Nasdaq
- Celcuity Non-GAAP EPS of -$1.21 beats by $0.32Seeking Alpha
- Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateREVTORPYK became commercially available on September 30th for the treatment of patients with HR+/HER2- PIK3CA wild-type locally advanced or metastatic breast cancerGlobeNewswire
- Celcuity To Participate in Upcoming Investor ConferencesMINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…GlobeNewswire
- Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference CallMINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of…GlobeNewswire
- Celcuity says Revtorpyk boosts progression-free survival in breast cancerSeeking Alpha
- Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastasesGlobeNewswire
- Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abirateroneGlobeNewswire
- Cantor sees ‘credible path to multi-billion-dollar peak sales’ for CelcuityInvesting.com
- New Strong Sell Stocks for October 14thADDYY, CELC and CNL have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2026.NasdaqCNL, CELC
- After-Hours Earnings Report for August 13, 2026 : AMAT, BAP, BLTE, CELC, HTFL, NKTR, DLO, STNE, TMC, GLOB, JCAP, ETONThe following companies are expected to report earnings after hours on 08/13/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Applied Materials, Inc. (AMAT)is reporting…NasdaqAMAT, BAP, BLTE, CELC